Newsletter
| Promoter: | MomentumOTC | Paying Party: | Emedia advisors |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| OXYS | $15000 | UNKNOWN |
| Max Profit: 7.07 % | Gain at close: 0.00 % | |
| *We think that this promoter is a part of a group of promoters. | ||
|
View This Email In Your Web Browser | Unsubscribe
|
Members,
So who's ready to end the week with some easy same-day gains?
Wednesday's +10% percent winner was nice, but we've just uncovered something with much more profit potential.
Our new pick is a true undervalued gem operating in the medical device sector.
Despite posting 14 consecutive growth quarters, the company is still only trading slightly above its 52-week low.
The company's stock has taken a beating over the past few months.
However, this unjustified decline in share price has just created the opportunity of a lifetime for traders.
Traders now have the chance to pick up shares at a near 80% discount from its 52-week high of $1.12.
Analysts agree that that the $0.24 share price does not reflect the obvious growth potential that the company has
A run back to its 52-week high would represent gains of +366.67%!
However some analysts are predicting that its share price will go much higher than that!
On November 25th 2015, SeeThruEquity, an unbiased equity research firm, gave a very bullish outlook on the company and slapped on a target price of $2.30!
A run to $2.30 would represent gains of +858.33%!
It doesn't take a genius to realize this company has plenty of room to run to the upside.
This appears to be the 'picture perfect' low-risk, high reward opportunity for traders!
Our new pick is as close to a sure thing as you're going to find tomorrow. and is your best bet for some easy same-day profit!
Members,
So who's ready to end the week with some easy same-day gains?
Wednesday's +10% percent winner was nice, but we've just uncovered something with much more profit potential
The company is called OxySure Therapeutics, Inc. (OXYS), and it's your best chance for end of the week profit.
OXYS is a true undervalued gem that is just itching to breakout for substantial gains.
Despite posting 14 consecutive growth quarters, the company is still only trading slightly above its 52-week low.
Here's the best part...
After a nice +14% rally to $0.27 on Tuesday, OXYS has retraced back down to a much more attractive entry level of $0.24.
With rock solid support established at at around $0.22, OXYS appears to be the 'picture perfect' low-risk, high reward opportunity for traders!
We are feeling confident that OXYS will touch $0.30 well before it ever drops below $0.20 again.
The company has been dropping blockbuster announcements almost daily, and we heard a rumor that they're planning to release huge news very shortly that could act as a major catalyst towards driving its share price up!
Based on its current share price and recent chart behavior, OXYS is as close to a sure thing as you're going to find tomorrow.
Add it to your watchlist now, and be ready to trade tomorrow morning at 9:30am EST!
About the Company
OxySure Therapeutics, Inc. (OXYS) is the world leader in shortduration/emergency duration medical oxygen and respiratory solutions for mass market use. Based in Texas, USA the company develops, manufactures and sells a safe and easy to use solution to produce medically pure oxygen from two dry inert, proprietary powders. OXYS has numerous patents issued and pending on this proprietary process and methodology that is revolutionizing the emergency short duration oxygen supply marketplace. With this technology, oxygen is generated on demand. There is no storage of oxygen. There are no compressed tanks, no dials, no valves, no regulatory maintenance, no hydrostatic testing, no batteries, no required training, and none of the hazards associated with traditional oxygen provision systems. OXYS makes the delivery devices lighter, safer, more affordable and easier to use.
OXYS improves access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health” (IDLH) environments. In addition to oxygen products for public/lay responder usage, OxySure also markets emergency medical solutions including AEDs (Cardiac Science, Philips, Zoll, Physio Control, Defibtech, and Heartsine), QuikClot Bleeding Control solutions, resuscitation products and pulse oximetry products.
The OXYS Model 615 is the world's first portable emergency oxygen device for mass lay person use. FDA cleared for over the counter sale, it allows any lay person - a bystander, colleague or loved one - to administer medical oxygen during those first critical minutes after a medical emergency occurs, while waiting for first responders to arrive. The product is also CE Marking approved, and has been used in thousands of saves.
OXYS recently launched its OxyTrac technology, which is a true game changer in the industry.
Suppose that you're at a sporting event and someone in the crowd suffers a heart attack and goes into cardiac arrest. A nearby fan responds quickly and calls for help, but stadium employees aren't quite sure where the nearest AED is located. Once a device is finally located, emergency responders attempt to utilize it, but the battery has died. The person ends up dying at the event and the sporting event is sued for their lack of an appropriate response.
To make sure these scenarios never occur, OXYS's OxyTrac technology helps rapidly locate all emergency response devices on the premises, facilitates availability of extra help via a contact database, and ensures that devices are properly inspected, while tracking expiration dates for batteries or other consumables.
OxyTrac is compatible with a wide array of emergency response devices, ranging from OxySure's in-house Model 615 emergency oxygen solution to AEDs produced from a variety of different manufacturers. At a price as low as $25 per device per year, the solution is a cost effective way to ensure appropriate emergency responses and legal compliance necessary to avoid lawsuits and other issues stemming from the lack of an appropriate response.
"We are excited about OxyTrac and the way it will make our customers' lives easier by consolidating the tracking, inspections, maintenance, and monitoring of all their emergency medical devices on one single platform," said Julian Ross, CEO of OxySure. "We are able to track any device with an expiry date on it, and OxyTrac can provide the confidence of knowing the filing, registration, and submission of the required compliance paperwork has been documented properly."
OxyTrac addresses a large potential end market - including its existing customer base - with a high margin recurring revenue service. The company has sold thousands of its own devices over the past several years, creating a strong initial market for the service, while there are millions of commercial AED installations around the world. Capturing even a fraction of these customer segments could generate significant recurring revenue for shareholders.
In addition to generating recurring revenue from the yearly subscription fee, the technology could improve the consistency of consumable revenue from its other products. The OxySure Model 615 has reusable oxygen cartridges that must be regularly replaced to remain effective and the reminders generated from OxyTrac(TM) could ensure a steady stream of orders for new cartridges from its existing customer base over the long-term. The system automatically generates email reminders regarding upcoming expiry dates and an even create autoship options with automatic invoicing for customer convenience.
We are anticipating a high demand for this cutting edge product in the very near future.
Strong Q4 sales could help drive OXYS's stock price to new all time highs.
This could be your opportunity to pick up shares at a ground-floor price!
Market Outlook:
OXYS reported its 14th consecutive quarter of growth during its fiscal third quarter, with revenue growing at a nearly 40% clip to $1,138,380 for the quarter. With plans to reach a $10 million run rate by the end of the year, the company's products continue to gain traction in the market, while new product launches like OxyTrac promise to create new growth opportunities. Combined with an anticipated cash flow breakeven next year, OXYS appears extremely undervalued at its current level.
The company also plans to pursue an uplisting to a national exchange like the NASDAQ or NYSE MKT, having appointed new board members and taken actions to meet other requirements. Upon a successful uplisting, the move could encourage institutional investors to take a closer look at the stock and potentially improve both liquidity and share price. Unbiased analysts like SeeThruEquity have assigned a $2.30 per share price target on the stock given these upcoming catalysts.
Fourteen (14) consecutive quarters of revenue growth (5 quarters at triple digit growth; 7 quarters at double digit growth)
Just look as some of these numbers:
- Revenue $3.4 million
- Revenue run rate ~ $5 million
- Margins 56% - 62%;
- Ave. annual growth rate over 3 years 216%
- Ave. quarterly growth rate over 14 quarters 243%
Here are a few other reasons why we believe OXYS's days of trading at under $0.30 are numbered.
Patented technology
Recurring revenue model
First mover advantage
Enormous end user markets
FDA cleared (OTC); CE Marking approved
Additional vertical markets
Technical Analysis:
OXYS's shares have taken a beating over the past few months.
This unjustified decline in share price has just created the opportunity of a lifetime for traders.
Traders now have the chance to pick up shares of OXYS at a near 80% discount from its 52-week high of $1.12.
Analysts agree that that OXYS's $0.24 share price does not reflect the obvious growth potential that the company has
A run back to its 52-week high would represent gains of +366.67%!
However analysts are predicting that OXYS's share price will go much higher than that!
On November 25th 2015, SeeThruEquity, an unbiased equity research firm, gave a bullish outlook on OXYS and slapped on atarget price of $2.30!
A run to $2.30 would represent gains of +858.33%!
That would be like turning $1,000 into $9,581 in just one trade!
Let's not forget the float on OXYS's is still relatively small at just 17.7M.
A nice burst in volume could send shares soaring for high double digit gains tomorrow.
We've already watched OXYS rally up for double-digit gains once this week....
After a nice +14% rally to $0.27 on Tuesday, OXYS has retraced back down to more much more attractive entry level of $0.24.
With rock solid support established at at around $0.22, OXYS appears to be the 'picture perfect' low-risk, high reward opportunity for traders!
We are feeling confident that OXYS will touch $0.30 well before it ever drops below $0.20 again.
OXYS is as close to a sure thing as you're going to find tomorrow.
Make sure you add it to the top of your watchlist, and have it pulled up on your trading screen today when the clock strikes 9:30am EST
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
For more information on OXYS, please visit their website: www.oxysure.com
|
Best Regards, |
The PennyStockLocks Team
P.S.
* Share the wealth by forwarding this email to your friends & family who have yet to join the fastest growing network of successful traders on the web!
Disclaimer:
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by PennyStockLocks LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “PennyStockLocks” refers to PennyStocklocks LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here.
PennyStockLock's business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars cash via bank wire by a third party, eMedia Advisors LLC., to conduct investor relations advertising and marketing for OXYS. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, PennyStockLock's often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
|
Best Regards, |
The MomentumOTC Team
P.S.
* Share the wealth by forwarding this email to your friends & family who have yet to join the fastest growing network of successful traders on the web!
Disclaimer:
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by PennyStockLocks LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “MomentumOTC” refers to PennyStocklocks LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here.
PennyStockLock's business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars cash via bank wire by a third party, eMedia Advisors LLC., to conduct investor relations advertising and marketing for OXYS. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, PennyStockLock's often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
|
This message was sent to xxxxxx@gmail.com from: MomentumOTC | alerts@momentumotc.com | PennyStockLocks, LLC | 300 Claremont Ave | Verona, NJ 07044 |
Email Marketing by |
Unsubscribe